美多巴对帕金森患者骨代谢与骨密度临床观察.docVIP

美多巴对帕金森患者骨代谢与骨密度临床观察 　　[摘要] 目的 ?^察美多巴对帕金森患者及正常同龄人骨代谢与骨密度的影响。 方法 选择2016年1月～2017年3月期间在我院就诊的帕金森病（Parkinsons disease，PD）患者45例为PD组及正常同龄人45例为对照组。检测两组受检者治疗前后血钙（Ca）、Ⅰ型前胶原氨基端前肽（PINP）和Ⅰ型胶原交联末端肽（CTX-1）水平，双能X线吸收法（dualenergy X-ray absorptiometry，DXA）检测两组髋部骨密度（BMD）与腰椎骨密度。 结果 PD患者血钙、PINP与25（OH）D3水平均低于对照组，差异有统计学意义（P0.05）。 结论 PD患者的血清钙、Ⅰ型前胶原氨基端前肽（PINP）、25-羟基维生素D3[25（OH）D3]水平均低于对照组；血清Ⅰ型胶原交联末端肽（CTX-1）高于对照组，提示PD患者存在骨代谢异常。美多巴可以改善因PD病导致的骨代谢异常、增加PD患者骨密度，并且对正常人群也有相同作用。 　　[关键词] 美多巴；帕金森；骨代谢；骨密度 　　[中图分类号] R742.5 [文献标识码] A [文章编号] 1673-9701（2018）10-0025-03 　　Clinical observation of madopar on bone metabolism and bone mineral density in patients with Parkinson 　　CHANG Xuejun 　　Department of Cerebral Surgery， Guangzhou First Peoples Hospital， Guangzhou 510180， China 　　[Abstract] Objective To observe the effect of madopar on bone metabolism and bone mineral density（BMD） in patients with Parkinson and their normal peers. Methods 45 patients with Parkinsons disease（PD） treated in our hospital from January 2016 to March 2017 were selected as PD group and 45 normal peers as control group. The level of blood calcium（Ca）， procollagen Ⅰ N-terminal propeptide（PINP） and C-terminal cross-linking telopeptide of type Ⅰ collagen（CTX-1） were measured before and after treatment in two groups. Dualenergy X-ray absorptiometry（DXA） was used to detect the hip BMD and lumbar BMD. Results The levels of serum calcium， PINP and 25（OH）D3 in PD patients were significantly lower than those in the control group（P0.05）. Conclusion The serum levels of calcium， PINP and 25（OH）D3 in PD patients are lower than those in the control group. Serum CTX-1 is higher than the control group， which suggest that patients with PD have abnormal bone metabolism. Madopar could reduce the abnormal bone metabolism due to PD， increase BMD in patients with PD， and also play the same role in general population. 　　[Key words] Madopar； Parkinson； Bone metabolism； Bone mineral density 　　帕金森病是一种常见的神经系统变性疾病，老年人多见，平均发病年龄为60岁左右。我国65岁以上人群PD的患病率大约